{
  "id": 18140698,
  "title": "Ingevity set to report earnings after streamlining portfolio",
  "url": "https://urgent.news/2026/11/04/ingevity-set-to-report-earnings-after-streamlining-portfolio",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-04T15:33:01.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/earnings/ingevity-set-to-report-earnings-after-streamlining-portfolio-93CH-5000306"
  },
  "original_language": "en",
  "account": "Ingevity Corp. is set to release its third-quarter earnings on Wednesday, providing a key indicator of whether the specialty chemicals firm can maintain margin improvements following its portfolio restructuring, even as revenue declines. Analysts forecast earnings of $1.56 per share on $304.6 million in revenue, a sequential drop from the previous quarter's $1.74 per share and $314.1 million in sales. The 16% revenue decline stems from Ingevity's strategic exit from lower-margin businesses earlier this year. While EPS forecasts have slightly decreased by 0.4% over two months, they remain relatively stable. Despite the near-term uncertainty, all three analysts covering the stock rate it as a strong buy, with an average price target of $89, suggesting a potential 21% increase from the current $73.63 share price. The projected sequential decline follows a strong second quarter, where Ingevity exceeded estimates by 29%, achieving adjusted earnings of $1.74 per share and an adjusted EBITDA margin of 36.6% from continuing operations. The company's focus has been on exiting non-core assets, including its refinery and Industrial Specialties products, which together generated $158 million in proceeds. Ingevity's performance in its remaining businesses, particularly in Performance Materials and Pavement Technologies, will be closely watched. The company raised its 2026 outlook in the second quarter, projecting adjusted EBITDA between $380 million and $400 million and adjusted EPS between $5.00 and $5.45. This upcoming earnings report will be crucial in determining whether Ingevity's strategy to focus on higher-margin products can withstand softer industrial demand and validate its strategic shift as the company celebrates its tenth year as a publicly traded entity.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}